利民控股集团股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人赵伟建，经 2018 年 10 月 26 日召开的公司 2018 年第三次临时股东大会选 举，担任第四届董事会独立董事，经 2021 年 10 月 25 日召开的公司 2021 年第四次 临时股东大会选举，担任第五届董事会独立董事。在任职期间严格按照《公司法》 《证券法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引》等有关法律法规及《公司章程》《公司独立董事工作制度》等内部控制制 度的规定和要求，诚信、勤勉、忠实地履行职责，认真审议董事会各项议案，对 重大事项发表独立意见，积极维护公司整体利益和中小股东的合法权益。现将 2024 年度本人履行独立董事职责情况述职如下： 一、出席董事会及股东大会的情况 2024 年度本人任职期间，公司共召开 8 次董事会会议，召开 5 次股东大会， 本人出席会议情况如下： | 本年应参加董事会 | 亲自出（次） | 委托出席（次） | 缺席（次） | 出席股东大会 | | --- | --- | --- | --- | --- | | 次数 | | | | 次数 | | 8 ...

利民控股集团股份有限公司 董事会关于独立董事独立性自查情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号--主板上市公司规范运作》等要求，利 民控股集团股份有限公司（以下简称"公司"）独立董事就其独立性进行了自查， 并向董事会提交了《2024年度独立董事关于独立性自查情况的报告》，董事会对在 任独立董事马建平、沈哲、刘亚萍、程丽的独立性情况进行评估并出具如下专项意 见： 经核查，公司独立董事马建平、沈哲、刘亚萍、程丽的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要 股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，符合《上市公司独立董事管理办法》《深圳证券交易 所上市公司自律监管指引第 1 号--主板上市公司规范运作》中对独立董事独立性 的相关要求。 利民控股集团股份有限公司董事会 2025 年 04 月 17 日 - 1 - ...

一、主要会计数据和财务指标 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 三、分红送配方案情况 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2300 | 0.1700 | 35.29 | 0.6000 | | 每股净资产（元） | 6.7 | 7.08 | -5.37 | 7.06 | | 每股公积金(元) | 2.26 | 2.26 | 0 | 2.28 | | 每股未分配利润(元) | 3.29 | 3.40 | -3.24 | 3.43 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 42.37 | 42.24 | 0.31 | 50.16 | | 净利润(亿元) | 0.81 | 0.62 | 30.65 | 2.19 | | 净资产收益率(%) | 3.01 | 2.23 | 34.98 | 8.01 | 前十大流通股东累计持有： 11885.14万股，累计占流通股比： 36 ...

Dividend Distribution - The company plans to distribute a cash dividend of 2.5 yuan per 10 shares to all shareholders, based on a total of 405,445,739 shares[4]. - The cash dividend distribution represents 100% of the total profit distribution amount, with available distributable profits amounting to 1,205,786,126.28 yuan[151]. - The company’s board of directors emphasizes a stable profit distribution policy, ensuring that cash dividends do not exceed the cumulative distributable profits and do not impair the company's ongoing operations[148]. - The company has distributed a total of 732 million in cash dividends over the past 8 years, maintaining a consistent dividend policy since its listing in 2015[106]. Financial Performance - The company's operating revenue for 2024 was approximately ¥4.24 billion, a slight increase of 0.32% compared to ¥4.22 billion in 2023[6]. - Net profit attributable to shareholders for 2024 reached ¥81.36 million, representing a significant increase of 31.11% from ¥62.05 million in 2023[6]. - The basic earnings per share for 2024 was ¥0.23, up 35.29% from ¥0.17 in 2023[6]. - The total assets at the end of 2024 were approximately ¥6.66 billion, a decrease of 2.28% from ¥6.82 billion at the end of 2023[6]. - The net cash flow from operating activities for 2024 was ¥373.83 million, down 20.70% from ¥471.39 million in 2023[6]. - The total operating revenue for 2024 reached ¥4,237,402,851.27, representing a year-on-year increase of 0.32% compared to ¥4,223,936,964.12 in 2023[50]. - The revenue from the pesticide segment was ¥3,824,458,242.21, accounting for 90.25% of total revenue, with a slight increase of 0.14% year-on-year[50]. - The veterinary medicine segment generated revenue of ¥381,789,651.93, which is a 3.29% increase from ¥369,626,735.12 in the previous year[50]. Risk Management - The company acknowledges various risks including market competition, raw material price fluctuations, and environmental risks, urging investors to remain aware of investment risks[4]. - The company has a comprehensive risk management strategy in place to address potential operational challenges[4]. - The company actively engages in risk management strategies to address foreign exchange fluctuations and customer default risks[80]. - The company has a comprehensive risk management framework in place, including measures for liquidity and credit risks[80]. Market and Industry Insights - The agricultural pesticide industry is expected to see a rigid demand due to the need for increased crop yields to meet future food requirements[27]. - China's pesticide export volume reached a historical high of 2.05 million tons in 2024, with a total value of ¥113.3 billion[28]. - The global biopesticide market is expected to grow from $9.5 billion in 2022 to $16.75 billion by 2027, with a CAGR of 12.0%[29]. - China's biopesticide market is projected to increase from approximately ¥210.2 billion in 2024 to ¥330.9 billion by 2027, achieving a CAGR of 17.1%[29]. Product Development and Innovation - The company is focusing on the development of green pesticides and has aligned with national policies promoting sustainable agricultural practices[27]. - The company is focusing on AI and biopesticide technology, achieving significant breakthroughs while maintaining its competitive edge[32]. - The company has successfully registered 8 new Class II veterinary drugs and 2 new Class III veterinary drugs, with 13 raw material products passing the new GMP certification[33]. - The company is developing multiple new products, including new herbicides and biopesticides, aimed at increasing profit growth points[64]. Environmental Compliance and Sustainability - The company has established a comprehensive environmental management system, including emergency response plans and pollution control measures[171]. - The company has implemented continuous monitoring systems across various production areas to ensure compliance with environmental regulations[169]. - The company has passed ISO9001 quality management and ISO14001 environmental management system certifications, demonstrating commitment to environmental management[171]. - The company is subject to various environmental protection regulations and standards, including the Pollutant Discharge Permit Management Measures effective from July 1, 2024[163]. Governance and Management - The company has established a three-tier governance structure for ESG initiatives, integrating global standards with local practices[49]. - The company emphasizes the importance of independent directors in decision-making, supervision, and professional consultation to safeguard investor interests[104]. - The company has established an ESG committee to promote sustainable development and align with international standards regarding environmental, social, and governance practices[105]. - The company has a complete and independent procurement, production, sales, and R&D system, allowing it to operate independently in the market[112]. Safety and Training - The company conducted 1,183 safety training sessions, with a total of 33,318 participants, enhancing safety management practices[49]. - The company has a dedicated safety management team consisting of 18 safety management personnel and 6 registered safety engineers[198]. - The company implemented a dual prevention mechanism for risk control and hazard identification, ensuring comprehensive coverage of safety risks[199]. - The company has not experienced any major safety incidents during the reporting period, indicating effective safety management practices[199]. Strategic Initiatives - The company plans to continue expanding its market presence and enhancing its product offerings through ongoing research and development[80]. - The company aims to improve its ESG rating from BBB to A in 2024, reflecting its commitment to sustainable development[49]. - The company plans to optimize its asset structure through mergers and acquisitions, cash dividends, and equity incentives to create greater shareholder value[96]. - The company is committed to driving research and development efficiency, leveraging AI technology to innovate and develop new products in the agricultural sector[96].

A股市场进入一季报业绩密集期披露。截至4月15日，已有267家上市公司发布一季度业绩预告或一季 报，其中243家公司业绩同比向好，占比逾九成。宁德时代（300750）、国泰海通、中远海控 （601919）、紫金矿业（601899）、比亚迪（002594）等多家行业龙头公司实现"开门红"。农林牧渔板 块则大幅扭亏为盈，养猪龙头牧原股份（002714）归母净利超40亿元。 5家公司净利润超100亿元 据证券时报.数据宝统计，截至4月15日，267家已发布第一季度相关报告公司中，5家公司净利润超过 100亿元(业绩预告取中值，下同)，依次为宁德时代、中国人保（601319）、国泰海通、中远海控和紫 金矿业。宁德时代盈利规模暂居榜首，为139.63亿元；国泰海通净利润实现翻倍，同比增幅375%。 宁德时代净利润增速远超营收增速，一季度实现营业收入847.05亿元，同比增长6.18%；归母净利润 139.63亿元，同比增长32.85%；扣非净利润118.29亿元，同比增长27.92%。公司经营活动现金流也表现 亮眼，流量净额为328.68亿元，同比增长15.91%。 宁德时代一季度电池销量超过120GWh，同比增长超过 ...

关于利民转债预计触发赎回条件的提示性公告 | 股票代码：002734 | 股票简称：利民股份 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：128144 | 债券简称：利民转债 | | 利民控股集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 自 2025 年 3 月 26 日至 2025 年 4 月 15 日，利民控股集团股份有限公司（以 下简称"公司"）股票已有 9 个交易日的收盘价不低于 "利民转债"当期转股价格 （即 8.35 元/股）的 130%（即 10.86 元/股），预计后续可能触发"利民转债"有 条件赎回条款。根据《公司公开发行可转换公司债券募集说明书》（以下简称《募 集说明书》）中有条件赎回条款的相关规定，届时公司董事会有权决定是否按照债 券面值加当期应计利息的价格赎回全部或部分未转股的"利民转债"。敬请广大投 资者详细了解可转换公司债券相关规定，并及时关注公司后续公告，注意投资风险。 一、可转换公司债券上市发行概况 （一）可转债发行情况 经中国证券监督管理委员会《关于 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 股票代码：002734 股票简称：利民股份 公告编号：2025-023 利民控股集团股份有限公司 关于子公司为子公司提供担保的公告 三、担保合同的主要内容 2、保证人：威远生化； 利民控股集团股份有限公司（以下简称"公司"）子公司河北威远生物化工股 份有限公司（以下简称"威远生化"）为河北威远药业有限公司（以下简称"威远 药业"）与招商银行股份有限公司石家庄分行签订的《授信协议》提供最高额保证 担保。 二、担保进展情况 2025 年 4 月 10 日，威远生化与招商银行股份有限公司石家庄分行签订了《最 高额不可撤销担保书》【编号：311XY250311T00018001】，威远生化为威远药业与 招商银行股份有限公司石家庄分行签订的《授信协议》【编号：311XY250311T000180】 提供 2,000 万元最高额保证担保。 1、债权人：招商银行股份有限公司石家庄分行； 3、被担保人：威远药业； 4、最高额保证：威远生化为威远药业与招商银行股份有限公司石家庄分行签 订的《授信协议》【编号：31 ...

股票代码：002734 股票简称：利民股份 公告编号：2025-022 利民控股集团股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、担保情况概述 利民控股集团股份有限公司（以下简称"公司"））分别于 2024 年 4 月 25 日、 2024 年 5 月 16 日召开第五届董事会第二十三次会议、2023 年度股东大会，审议通 过了《关于 2024 年度为子公司提供担保额度预计的议案》。同意公司为河北威远 生物化工股份有限公司（以下简称"威远生化"）在 2024 年度合计不超过人民币 63,500 万元的银行债务提供连带责任保证担保。有效期自公司 2023 年度股东大会 审议通过后至公司 2024 年度股东大会审议相关担保额度议案之日止。具体内容详 见公司于 2024 年 4 月 26 日在指定信息披露媒体《证券时报》《中国证券报》和巨 潮资讯网（http://www.cninfo.com.cn）披露的《公司关于 2024 年度为子公司提 供担保额度预计的公告》（公告编号：2024-026）。 二、担保进展情况 ...

Core Viewpoint - The A-share market is experiencing increased volatility, with a significant divergence in risk appetite among investors. High-growth companies are becoming focal points for institutional investment as they report strong earnings forecasts, while defensive assets and consumer sectors are also attracting attention due to their stability in uncertain market conditions [1][2]. Group 1: Market Trends and Institutional Strategies - The recent surge in market volatility has led to a shift in institutional strategies, focusing on high-growth stocks and defensive assets. Funds are particularly interested in sectors supported by policy and those with low valuations [2][11]. - Notable high-growth stocks such as Limin Co. and Yinglian Co. have seen significant price increases, with Limin Co. expected to report a net profit growth of 1504.79% for Q1 [2][3]. Group 2: Company Performance Highlights - Limin Co., which specializes in agricultural chemicals, anticipates a non-GAAP net profit growth of 985.99% to 1199.85% in Q1, driven by rising product prices and increased sales [3]. - Yinglian Co. projects a net profit of 7.5 million to 11 million yuan for Q1, reflecting a year-on-year growth of 459.28% to 720.28%. The company attributes this growth to successful market expansion and improved margins on its products [4][5]. Group 3: Fund Activity and Stock Holdings - Fund managers have increased their holdings in high-growth stocks like Yinglian Co., with 11 public funds acquiring a total of 158,150 shares by the end of 2024, indicating a growing interest in this stock [8]. - Limin Co. has also seen a rise in institutional interest, with 59 public funds holding a total of 6,393,759 shares by the end of 2024, compared to only two funds in the previous year [9]. Group 4: Investment Focus and Recommendations - Investment firms are recommending a focus on domestic demand and dividend-paying assets, particularly in light of ongoing tariff uncertainties. They suggest that sectors with lower exposure to U.S. trade may outperform in the current environment [11][12]. - There is a consensus among fund managers to prioritize sectors such as financials, real estate, and new consumer trends, as well as to consider opportunities in industries with strong pricing power and high margins [11][12].

基础化工/农化制品 利民股份（002734.SZ） 阿维菌素等产品价格上涨，Q1 业绩预告超预期 2025 年 04 月 09 日 投资评级：买入（维持） | 日期 | 2025/4/9 | | --- | --- | | 当前股价(元) | 11.57 | | 一年最高最低(元) | 11.97/6.09 | | 总市值(亿元) | 42.63 | | 流通市值(亿元) | 37.74 | | 总股本(亿股) | 3.68 | | 流通股本(亿股) | 3.26 | | 近 3 个月换手率(%) | 329.87 | 股价走势图 数据来源：聚源 -24% 0% 24% 48% 72% 2024-04 2024-08 2024-12 2025-04 利民股份 沪深300 相关研究报告 《农药一体化龙头，或受益于百菌清 和代森锰锌上涨—公司深度报告》 -2024.12.5 ——公司信息更新报告 | 金益腾（分析师） | 张晓锋（分析师） | 宋梓荣（联系人） | | --- | --- | --- | | jinyiteng@kysec.cn | zhangxiaofeng@kysec.cn | songzir ...